{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:28:53Z","timestamp":1792250933992,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016915","name":"Inventiva Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002913","name":"Government of Flanders","doi-asserted-by":"publisher","award":["11B0723N"],"award-info":[{"award-number":["11B0723N"]}],"id":[{"id":"10.13039\/501100002913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002913","name":"Government of Flanders","doi-asserted-by":"publisher","award":["1843824N"],"award-info":[{"award-number":["1843824N"]}],"id":[{"id":"10.13039\/501100002913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002913","name":"Government of Flanders","doi-asserted-by":"publisher","award":["1802624N"],"award-info":[{"award-number":["1802624N"]}],"id":[{"id":"10.13039\/501100002913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002913","name":"Government of Flanders","doi-asserted-by":"publisher","award":["1227824N"],"award-info":[{"award-number":["1227824N"]}],"id":[{"id":"10.13039\/501100002913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002913","name":"Government of Flanders","doi-asserted-by":"publisher","award":["1805718N"],"award-info":[{"award-number":["1805718N"]}],"id":[{"id":"10.13039\/501100002913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003441","name":"Universitair Ziekenhuis Gent","doi-asserted-by":"publisher","award":["FIKO19-TYPE2-006"],"award-info":[{"award-number":["FIKO19-TYPE2-006"]}],"id":[{"id":"10.13039\/501100003441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1227824"],"award-info":[{"award-number":["1227824"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.biopha.2025.117826","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T04:53:37Z","timestamp":1736657617000},"page":"117826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature"],"prefix":"10.1016","volume":"183","author":[{"given":"Anneleen","family":"Heldens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Casteleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Onghena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Antwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Neyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vanhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Verhelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Raevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Van Vlierberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Devisscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Junien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Wettstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Lefere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.117826_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(23)00438-7","article-title":"Pathophysiology and therapeutic options for cirrhotic portal hypertension","author":"Guix\u00e9-Muntet","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.117826_bib2","first-page":"1449","article-title":"Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis","author":"Francque","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol. 22"},{"key":"10.1016\/j.biopha.2025.117826_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","article-title":"Pathophysiology of Portal Hypertension","volume":"18","author":"Iwakiri","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.biopha.2025.117826_bib4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.117826_bib5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/hep.26219","article-title":"Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models","volume":"57","author":"Coulon","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.117826_bib6","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.068","article-title":"Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension","volume":"137","author":"Van Steenkiste","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.117826_bib7","article-title":"Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.biopha.2025.117826_bib8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.01.025","article-title":"Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats","volume":"60","author":"Schwabl","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.117826_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPAR\u03b1 activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodr\u00edguez-Vilarrupla","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.117826_bib10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages\u2606","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.117826_bib11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117826_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117826_bib13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117826_bib14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.117826_bib15","doi-asserted-by":"crossref","unstructured":"S. Van Campenhout, H. Van Vlierberghe, L. Devisscher, Common Bile Duct Ligation as Model for Secondary Biliary Cirrhosis, in: 2019: pp. 237\u2013247. https:\/\/doi.org\/10.1007\/978-1-4939-9420-5_15.","DOI":"10.1007\/978-1-4939-9420-5_15"},{"key":"10.1016\/j.biopha.2025.117826_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/HEP.0000000000000557","article-title":"Osteopontin characterizes bile duct\u2013associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis","volume":"79","author":"De Muynck","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.117826_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2613.2008.00597.x","article-title":"Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation","volume":"89","author":"Geerts","year":"2008","journal-title":"Int J. Exp. Pathol."},{"key":"10.1016\/j.biopha.2025.117826_bib18","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117826_bib19","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.117826_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.biopha.2025.117826_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025656","article-title":"Von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis","volume":"9","author":"Zou","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopha.2025.117826_bib22","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","article-title":"Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?","volume":"53","author":"Thabut","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.117826_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5604\/16652681.1198799","article-title":"Angiogenesis and portal-systemic collaterals in portal hypertension","volume":"15","author":"Gana","year":"2016","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.biopha.2025.117826_bib24","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41598-020-59286-8","article-title":"Imaging and pathological features of idiopathic portal hypertension and differential diagnosis from liver cirrhosis","volume":"10","author":"Zhao","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.117826_bib25","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/hep.24238","article-title":"Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice","volume":"53","author":"Van Steenkiste","year":"2011","journal-title":"Hepatology"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T01:51:03Z","timestamp":1746755463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"alternative-id":["S0753332225000204"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117826","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117826"}}